行情

SBBP

SBBP

Strongbridge
NASDAQ

实时行情|Nasdaq Last Sale

3.110
+0.130
+4.36%
交易中 13:16 01/28 EST
开盘
2.960
昨收
2.980
最高
3.170
最低
2.960
成交量
34.23万
成交额
--
52周最高
5.69
52周最低
1.430
市值
1.69亿
市盈率(TTM)
3.297
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SBBP 新闻

  • 强生称正在研发新型冠状病毒防疫疫苗
  • 新浪财经.59分钟前
  • 里士满联储1月制造业指数升至2018年以来的最高水平
  • 新浪财经.1小时前
  • 美国1月消费者信心指数涨幅超预期 升至5个月来高点
  • 新浪财经.1小时前
  • 疫情掀起央行政策预期调整 欧洲出现大举降息押注
  • 新浪财经.1小时前

更多

所属板块

制药
+0.43%
制药与医学研究
+0.59%

热门股票

名称
价格
涨跌幅

SBBP 简况

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
展开

Webull提供Strongbridge Biopharma plc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。